TCT与HPV-DNA检测在宫颈癌及癌前病变诊断中的应用

Application of TCT and HPV-DNA in Diagnosis of Cervical Cancer and Precancerous Lesion

目的探讨液基薄层细胞学检查技术(TCT)与高危型人乳头瘤病毒DNA(HPV-DNA)检测在宫颈癌及癌前病变中的应用价值。方法选取2014年2月至2015年3月在我院妇产科行宫颈细胞学检查者2000例行液基薄层细胞学检查(TCT)联合HPV-DNA检测,对TCT阳性、HPV-DNA阳性的668例患者做病理诊断对照分析。结果 TCT阴性患者中,存在HPV-DNA阳性的患者,占2.2%;TCT阳性的579例患者中,随着细胞学级别的增高,病理级别逐渐增高(r=0.996,P<0.05);随着病理级别的升高,HPV和TCT均为阳性的检出率随之升高(r=0.981,P<0.05)。结论 TCT联合HPV-DNA检测是减少宫颈癌及癌前病变漏诊的最佳筛查方法。

Objective To investigate the application value of TCT and HPV-DNA in cervical cancer and precancerous lesions. Methods From February 2014 to March 2015, 2000 cases of cervical cytology in our hospital were examined by HPV-DNA and 668 patients with TCT positive and HPV-DNA positive. Results In TCT negative patients, there were 2.2% patients with HPV-DNA positive, in 579 patients with TCT positive, the pathological grade gradually increased with the the cytological level（r=0.996, P〈0.05）, and the positive rate of both TCT and HPV increased with the increase of the pathological grade（r=0.981, P〈0.05）. Conclusion TCT combined with HPV-DNA detection is the best method to reduce the missed diagnosis of cervical precancerous lesions.